Shares of Advaxis (ADXS +0.00%), a clinical-stage biotech company focused on developing cancer immunotherapy vaccines, surged by 154% during the first six months of 2015. Backed out over the trailing ...
Shares of Advaxis, Inc. (NASDAQ: ADXS) were trading higher by nearly 3 percent at $9.66 on Tuesday after the company announced the establishment of a new scientific advisory board. Advaxis is a ...
New York, NY / ACCESSWIRE / November 24, 2014 / Advaxis, Inc. (ADXS) today published a new blog post on The Chairman’s Blog, written by the Company’s CEO, Daniel J. O’Connor. TheChairmansBlog.com is ...
PRINCETON, N.J., March 19, 2015 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, announced that the first patient was dosed in ...
PRINCETON, N.J., Feb. 11, 2015 -- Advaxis, Inc. (Nasdaq:ADXS), a clinical-stage biotechnology company developing cancer immunotherapies, has entered into a clinical trial collaboration agreement with ...
We are just a few weeks into the year, and already shares of Advaxis ( ADXS) are up by more than 60%. But that's nothing. The shares have fully quadrupled since their November lows. Advaxis stock has ...
PRINCETON, N.J.--(BUSINESS WIRE)-- Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, reported preliminary data on the ...
PRINCETON, N.J., July 06, 2016 (GLOBE NEWSWIRE) -- Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced that it reached an agreement ...
PRINCETON, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced ...
Advaxis announces restructuring with 24% of the workforce being cut and a change of the programs in its pipeline. The company announced that it will give itself a limited amount of time to partner the ...
PRINCETON, N.J.--(BUSINESS WIRE)--Daniel J. O’Connor, chief executive officer, president and board member of Advaxis, Inc. (NASDAQ: ADXS), a late-stage biotechnology company focused on the discovery, ...
Advaxis stock has recently quadrupled from $3 to as high as $13. Management has a history of promotional and misleading activities, including heavy use of the Dream Team Group. Tumor response data for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results